A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors

Phase 2

Completed

Conditions: erectile dysfunction
impotence
10013356

Registration Number: NL-OMON34486

Lead Sponsor: Bayer

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

-Written informed consent signed before any study-specific procedure
-History of ED for at least 6 months prior to screening, defined as the inability to achieve and maintain an erection of the penis sufficient to complete satisfactory sexual intercourse;(1) the diagnosis of ED has to be confirmed by a physician
-Stable, heterosexual relationship for at least 6 months prior to screening
-Aged 18 to 64 years (inclusive) at the first screening examination
-Highly motivated to obtain treatment for ED
-History of previous use of at least 1 marketed PDE5 inhibitor and insufficient therapeutic efficacy despite use of the highest approved dose
-Ability to understand and follow study-related instructions
-At least 4 attempts at sexual intercourse on 4 separate days during the open-label run-in phase with use of 20 mg vardenafil approximately 1 hour before attempting intercourse (according to the answer to the following question in the Subject Diary: Was sexual activity initiated with the intention of intercourse?)
-IIEF EF score <17
-At least 50% of attempts at sexual intercourse during the open-label run-in phase were unsuccessful, i.e. the following question in the Subject Diary will have to be answered with No:
-Did your erection last long enough for you to have successful intercourse? (SEP 3: success in maintenance of erection)
-Highly motivated to obtain treatment for ED
-Ability to understand and follow study-related instructions

Exclusion Criteria

-Incompletely cured pre-existing diseases that may influence absorption, distribution, metabolism, elimination, or effects of the study drugs
-Known hypersensitivity to the study drugs (active substances or excipients of the formulations)
-Known severe allergies, non-allergic drug reactions, or multiple drug allergies
-Any underlying cardiovascular condition, including unstable angina pectoris that would preclude sexual activity
-History of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to screening
-Bleeding disorder
-History of prostatectomy due to prostate cancer, including nerve-sparing techniques. Clarification: Any surgical procedures for the treatment of benign prostatic hypertrophy (BPH) are permitted, with the exception of cryosurgery, cryotherapy, and cryoablation
-Hereditary degenerative retinal disorders such as retinitis pigmentosa
-History of loss of vision due to non-arteritic anterior ischemic optic neuropathy (NAION), temporary or permanent loss of vision, including unilateral loss of vision
-History of uni- or bilateral hearing loss
-Presence of penile anatomical abnormalities such as penile fibrosis or Peyronie's disease which, in the investigator's opinion, would significantly impair sexual performance
-Primary hypoactive sexual desire
-History of spinal cord injury
-Moderate or severe hepatic impairment, i.e. Child-Pugh class B and C
-Clinically significant chronic hematological disease which may lead to priapism such as sickle cell anemia, multiple myeloma, or leukemia
-Active peptic ulceration
-History of syncope within 6 months prior to screening
-History of malignancy within the 5 years prior to screening (other than squamous or basal cell skin cancer)
-Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
-Diseases within the 4 weeks prior to screening that are considered clinically relevant by the investigator
-Concomitant use of nitrates or nitric oxide donors (from screening until the end-of-treatment visit)
-Concomitant use of anti-androgens. Clarification: 5* reductase inhibitors, commonly not classified as anti-androgens, are permitted
-Concomitant use of * adrenergic blockers (within 2 days prior to screening until the end-of-treatment visit)
-Use of moderate or potent inhibitors of cytochrome P450 (CYP) 3A4 within 2 weeks prior to screening: human immunodeficiency virus (HIV) protease inhibitors such as ritonavir or indinavir, azole-type antimycotic agents such as itraconazole or ketoconazole (topical forms are allowed), or macrolide antibiotics such as clarithromycin and erythromycin
-Use of potent inducers of CYP3A4 such as carbamazepine, phenytoin, or rifampicin within 2 weeks prior to screening
-Use of medication known to prolong the QT interval such as type Ia or type 3 anti-arrhythmics within 2 weeks prior to screening
-Concomitant use of any treatment for ED during the study including oral medication, vacuum devices, constrictive devices, injections, urethral suppositories, gels, any over-the-counter or non-prescription medications, or products purchased via the internet
-Use of other medication within 2 weeks prior to screening which could interfere with the study treatment
-Suspici